contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


episurf-year-end-report-1-january-31-december-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Episurf Medical operates in the medical technology industry and focuses on the development and manufacture of individually adapted implants for joint repair. The company's products are aimed at surgeons and healthcare institutions. The business is global with a main presence in Europe, North America and Asia. Episurf Medical was founded in 2008 and is headquartered in Stockholm, Sweden.

Episurf Medical

72% growth in customer base and 43% growth in gross order intake510(k) clearance received for Episealer® Patellofemoral System, and timetable communicated for 510(k) application for Episealer...

<ul><li>72% growth in customer base and 43% growth in gross order intake</li><li>510(k) clearance received for Episealer® Patellofemoral System, and timetable communicated for 510(k) application for Episealer MTP-System</li><li>Strengthening of commercial organization and preparation for US launch ongoing</li></ul><p>"Today we are reporting on yet another quarter with clear steps in the right direction. The key metric of the number of surgeons using the Episealer grew by 72% in the quarter, and gross order intake was up by 43%. We clearly experienced positive developments in our commercial activities during the end of the year. Within product development, we concluded the year with a major milestone being achieved - namely, the 510(k)-clearance for the Episealer® Patellofemoral System. In 2023, it is important that we take the next steps as a company, broadening the user base globally, including the marketing of our first commercially available product in the US," says Pål Ryfors, CEO Episurf Medical.</p>Fourth quarter 2022 compared to 2021, Group<ul><li>Gross order intake amounted to SEK 2.2m (1.6)</li><li>Order book amounted to SEK 2.0m (1.3)</li><li>Group net sales amounted to SEK 1.8m (1.5)</li><li>Loss for the period amounted to SEK -23.7m (-18.9)</li><li>Earnings per share amounted to SEK -0.09 (-0.08)</li></ul>Twelve months 2022 compared to 2021, Group<ul><li>Gross order intake amounted to SEK 7.1m (6.5)</li><li>Group net sales amounted to SEK 6.6m (6.5)</li><li>Loss for the period amounted to SEK -77.3m (-69.3)</li><li>Earnings per share amounted to SEK -0.29 (-0.31)</li></ul><p>&nbsp;</p>Significant events during the fourth quarter<ul><li>Episurf Medical received FDA 510(k) clearance for Episealer® Patellofemoral System</li><li>Episealer® Knee technology and clinical results were presented at scientific congresses in the US and Poland</li><li>Episurf Medical presented commercial focus areas at the company's Capital Markets Day</li></ul>